An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsDopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeysMolecular imaging of movement disordersProspects for new restorative and neuroprotective treatments in Parkinson's diseaseNeurotrophic factors as a therapeutic target for Parkinson's diseaseParkin promotes degradation of the mitochondrial pro-apoptotic ARTS proteinReduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy.Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.Longitudinal follow-up of SWEDD subjects in the PRECEPT Study[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative DiseasesOptimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's diseaseREM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease.Accelerating image reconstruction in dual-head PET system by GPU and symmetry properties.Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's diseaseNoninvasive imaging of islet grafts using positron-emission tomography.The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseaseDisease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulationCritical aspects of clinical trial design for novel cell and gene therapies.Applications of positron emission tomography (PET) in neurology.A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.Functional imaging in Parkinson's disease and dementia with Lewy bodies.Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signsNeurodegeneration and neuroprotection in Parkinson disease.Biomarkers and surrogate markers: an FDA perspective.Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease.Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studiesDietary fats, cholesterol and iron as risk factors for Parkinson's disease.Dopamine overdose hypothesis: evidence and clinical implications.Medical records documentation of constipation preceding Parkinson disease: A case-control study.Cell-based therapeutic approaches for Parkinson's disease: progress and perspectives.Parkinson's disease--the continuing search for biomarkers.
P2860
Q21129423-C98A7DD3-B865-42B5-AD9D-A6E97BF0FD3DQ27316473-A4E49904-0427-4A38-916A-03456273DA91Q28071336-FB095E17-51FB-4775-A834-79D10D68DFF8Q28138668-23E0CD0C-86E9-4567-A28C-E391BD8B4F26Q28273071-B845FFB8-0C77-4947-824C-92DFF62B65CAQ28727358-8811EFD3-1CDE-481C-9212-FE39B37A9AFCQ30439165-FEA1C757-FD8E-45BF-A213-21E36464A780Q30538394-69B7F1E6-5CEB-46AC-9BC1-A815E722A7B2Q30578973-3B669C61-84BA-4DDC-9FD9-B8AF7E34D7CDQ32052220-7DE8DE72-A529-47B9-8D79-DEDE3C7D7CF4Q33624586-FCF4C053-0020-4466-A117-E9B3F239D402Q33898436-47CA2D23-A901-4717-B741-A88F6A2D4A18Q34053259-64BDFC99-4104-4B97-A0AC-AE66BD75137CQ34094008-DE37036B-795D-4390-A066-86CBB440B926Q34327144-FEE8706E-2636-4BEA-835F-61A162673020Q34540036-CFFAB499-C113-4D60-8727-767B8936E5B4Q34827117-6F5922A4-2DE5-4F98-8134-494563D1AF63Q34983969-3BF31D7E-F85B-433C-ABD6-0FE68850B728Q35034718-8660FC6B-D85B-44D2-8532-885665605660Q35147766-719FA049-B9C5-4FBC-946D-B3D2D8C86501Q35452760-F7CB87BA-16B6-4CB4-8CDF-3287CC849044Q35471953-FD14E489-90D1-43DF-875E-BD9A71575172Q35490116-6F54ED1D-A19D-4885-B148-BF751ECD524AQ35664438-CFCE5070-D2DC-44D9-90ED-3F8B8F3BB355Q35748290-4E403B2F-EDC2-485F-8AF0-F709071BCF82Q35752869-393D1621-23FB-45FE-8CDC-486733C085A4Q35863417-3E9FB810-1B17-4D84-BBC0-1FE71F49D4BFQ35922870-E6650D90-456E-449D-9DA6-A0BF7CC71427Q35980553-957CC7C5-A23B-43DB-A19E-6B13120417AFQ36045259-252E6CFF-27AD-4D8B-972D-F06C979B6F67Q36045270-415CF9EA-4762-4B69-894C-18B2B1B0DC18Q36088218-0CE54EB0-E42E-4D09-B1CF-6510C79D075FQ36129732-8FB66371-2D44-4F39-B211-FB746BF18A07Q37090163-EBB76CB4-F16C-433F-ACB4-1B1152E78EF1Q37105104-9040C18C-99E8-4768-AE12-26BFB11C8D7AQ37362433-CA84ADA9-90D1-400F-A1FA-8A101A6520D3Q37384960-8A6AA332-F920-43A3-8768-FBD319364C2EQ37459723-E89FD954-B180-4DF8-8602-70DE0A28E079Q37732186-63592B17-DD8A-4013-9C76-0FC09779F5F1Q37834648-63AF36DD-A012-4E0A-86CC-19259855DDF8
P2860
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@en
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@nl
type
label
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@en
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@nl
altLabel
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
@en
prefLabel
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@en
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@nl
P50
P356
P1433
P1476
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.
@en
P304
P356
10.1093/BRAIN/119.2.585
P4011
c1b15d2825a42824eac8beaa1ae39b5c32bdf121
P407
P478
119 ( Pt 2)
P577
1996-04-01T00:00:00Z